Rocket Lab SEC Filings

Frank Klein, Chief Operations Officer of Rocket Lab USA, sold 44,553 shares on 03/14/2025 via automatic sell-to-cover for RSU tax withholding and 1,835 shares on 03/17/2025 pursuant to a 10b5-1 plan. Post-transaction, he owns 1,417,644 shares directly. This is a neutral signal as both sales are non-discretionary and routine.

Rocket Lab USA officer Arjun Kampani filed Form 144 on 3/17/2025 to sell 5,277 common shares acquired via RSUs on 3/13/2025, valued at $99,260. The sale follows a Rule 10b5-1 plan adopted 12/12/2024 and a recent sale of 28,836 shares on 3/14/2025 for $524,276. This routine disclosure signals no material adverse information.

This Form 144 filing notifies the proposed sale of 1,835 common shares by Rocket Lab officer Frank Klein, acquired via RSUs vesting on March 13, 2025, with an aggregate market value of $34,516. Klein recently sold 44,553 shares on March 14, 2025, for $810,031. The sale follows a Rule 10b5-1 trading plan adopted December 13, 2024, providing investors transparency on insider transactions.

This Form 144 discloses officer Adam C. Spice's intent to sell 62,843 common shares of Rocket Lab USA, Inc. The shares stem from 114,845 restricted stock units vesting on March 13, 2025, with the sale on March 14, 2025, via Morgan Stanley to cover tax obligations. No prior sales in the past 3 months; routine liquidity event for investors.

Form 144 discloses officer Frank Klein's proposed sale of 44,553 common shares valued at $810,031. Shares from 81,250 RSUs vesting 3/13/2025 as compensation; sale covers tax obligations. Routine insider transaction relevant for monitoring executive activity.

Rocket Lab officer Arjun Kampani filed Form 144 on 2025-03-14 notifying proposed sale of 28,836 common shares (7,740 + 21,096) valued at ~$524,276 via Morgan Stanley. Shares stem from restricted stock units vesting on 2025-03-15 as compensation, with portion for tax obligations. Routine insider transaction with no prior sales in past 3 months; relevant for tracking executive liquidity.

This is an automatic shelf registration statement (S-3ASR) filed March 11, 2025, allowing Rocket Lab and selling securityholders to offer securities from time to time. Key facts include authorization for common stock, preferred stock, debt securities, warrants, and units, with reference to Series A Preferred Stock held by CEO Peter Beck's trust. It is relevant to investors as it provides flexibility for future capital raises without additional SEC filings.

This 424B5 is an at-the-market offering prospectus supplement under shelf registration 333-285707 for up to $500M common stock. Key facts include 3% max commission, use of proceeds for growth/acquisitions including potential Mynaric deal, and dilution of ~$15.49 per share at $17.12 price. Relevant to investors as it signals potential equity raises and M&A funding.

Rocket Lab entered a Sales Agreement on March 11, 2025, to offer and sell up to $500M in common stock through agents including BofA Securities and others. Sales are at-the-market, with no obligation to sell any shares. The agreement supports a new shelf registration on Form S-3, filed and effective the same day.

Rocket Lab achieved record annual revenue of $436.2 million for 2024, driven by a 60% increase in launch cadence. The company continues to scale its space systems segment and remains on track for the Neutron rocket debut in late 2025.